Welcome to our dedicated page for SiNtx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on SiNtx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is a pioneering advanced ceramics company, renowned for its development and production of medical-grade silicon nitride. This innovative biomaterial is not only ideal for spinal fusion applications but also boasts a variety of medical uses due to its unique nanosurface texture. This texture promotes bone growth, offers excellent imaging capabilities, and demonstrates antibacterial properties.
Originally known for its research, development, and commercialization of silicon nitride-based medical devices, SINTX has expanded its horizons. Today, the company is involved in a wide array of biomedical, technical, and antipathogenic applications. SINTX's biomedical products are celebrated for their biocompatibility, bioactivity, and exceptional bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in patients across the United States, Europe, Brazil, and Taiwan.
SINTX Technologies operates the only FDA-registered and ISO 13485 certified silicon nitride medical device manufacturing facility in the world. Their robust sales and distribution network underpins their commitment to delivering innovative healthcare solutions that significantly enhance patient quality of life.
In addition to medical devices, SINTX is actively engaged in developing solutions for various technical and antipathogenic applications. These efforts include the creation of advanced ceramic materials designed to meet the evolving needs of multiple industries.
- Core Business: Manufacturing of medical-grade silicon nitride and advanced ceramics for diverse applications.
- Recent Achievements: Successful implantation of silicon nitride spinal implants in multiple countries.
- Current Projects: Expansion into technical and antipathogenic ceramic solutions.
- Partnerships: Collaborations with healthcare providers and research institutions globally.
- Financial Condition: Continuously innovating to maintain a strong market presence and financial stability.
Stay updated with the latest news from SINTX Technologies, as they continue to push the boundaries of advanced ceramics and medical innovation.
SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for patent application no. 17/237,687, titled 'Methods of Silicon Nitride Laser Cladding.' The patent covers a method for laser bonding bioactive silicon nitride to various biomedical implant substrates, including titanium, alumina, zirconia, and advanced polymers.
This technology complements their recently granted U.S. Patent (US 12162807) and enhances traditional implant materials with silicon nitride's osseointegration and bacterial resistance properties. As the only FDA-registered producer of implantable silicon nitride, SINTX has developed the material in both monolithic and particulate forms for various applications.
The company's intellectual property portfolio now includes 17 issued U.S. patents and 84 pending patent applications worldwide.
SINTX Technologies (NASDAQ: SINT) has signed a Joint Development Agreement with NED Medical to develop advanced ceramic-based microspheres for cancer treatment. The collaboration focuses on manufacturing microspheres containing Yttrium-90 radioisotope for transarterial radioembolization (TARE) treatment of hepatocellular carcinoma. The engineered microspheres, known as CombiSphere, feature unique properties including radiopacity and porosity, allowing for targeted chemotherapy and combination therapies. SINTX will support NED Medical's pre-clinical testing needs and transition the microsphere process from R&D to pilot production.
SINTX Technologies (NASDAQ: SINT) has appointed Gregg R. Honigblum as Chief Strategy Officer (CSO). Honigblum brings over 35 years of experience in healthcare and emerging growth companies, with a background in Wall Street and investment banking. He co-founded Creation Capital and Creation Capital Advisors, and has raised over half a billion dollars throughout his career. Notable achievements include providing early-stage capital for Myriad Genetics and being an early investor in Acacia Biosciences, which was later acquired by Merck for $620 million. In his new role, Honigblum will oversee corporate strategy and enhance investor relations.
SINTX Technologies (NASDAQ: SINT) has announced a stock repurchase program authorized by its Board of Directors to buy back up to $500,000 of outstanding common stock, representing approximately 20% of total outstanding shares. The repurchases will be conducted over several quarters based on market conditions. Maxim Group, will manage the program, which can be suspended or discontinued at the company's discretion. The initiative aims to optimize capital structure, reduce outstanding shares, and enhance earnings per share for remaining shareholders.
SINTX Technologies (NASDAQ: SINT) reported strategic updates for Q3 2024, highlighting its shift towards the medical device industry. The company ceased its armor division operations, resulting in a $4.5 million impairment charge. Financial highlights include an 18% year-over-year revenue increase and improved liquidity with $4.8 million in cash, up from $3.3 million at end-2023. The company raised $9.4 million year-to-date through strategic offerings. SINTX implemented workforce reductions and is exploring potential mergers, acquisitions, and strategic partnerships while focusing on leveraging its silicon nitride technology in medical applications.
SINTX Technologies (NASDAQ: SINT), an advanced materials company specializing in ceramics, has announced two key executive promotions. Ryan Bock, PhD, has been promoted to Chief Technology Officer (CTO) of SINTX Technologies, while Ann Kutsch has been named President of SINTX Technology Assessment and Transfer (SINTX TA&T), a subsidiary of SINTX.
As CTO, Dr. Bock will lead the strategic development of SINTX's advanced materials technologies and innovation pipeline. Ms. Kutsch will focus on expanding the company's intellectual property portfolio and transitioning key innovations to commercialization. These promotions reflect SINTX's commitment to advancing cutting-edge ceramic technologies for biomedical, aerospace, and industrial applications.
Eric K. Olson, President and CEO of SINTX Technologies, expressed excitement about the promotions, emphasizing the importance of Dr. Bock's and Ms. Kutsch's expertise and vision in advancing the company's mission.
SINTX Technologies and Prodways are jointly hosting a webinar titled 'Innovations in Ceramic Manufacturing: The Role of 3D Printing' on September 24th at 9:00 AM EDT/3:00 PM CEST. The event, organized with TCT Magazine, aims to explore the impact of additive manufacturing on ceramic applications.
The partnership between SINTX and Prodways combines Prodways' 3D printer manufacturing expertise with SINTX's advanced chemical formulations for additive powders and resins. This collaboration focuses on developing Digital Light Processing (DLP) printing for ceramic materials, complementing SINTX's existing expertise in Fused Filament Fabrication (FFF) printing of Silicon Nitride filled filament for biomedical applications.
The webinar will cover insights into how additive manufacturing is transforming ceramic production, innovations in ceramic 3D printing, and discussions on expanding possibilities in industries such as healthcare, aerospace, and defense.
SINTX Technologies (NASDAQ: SINT) has successfully completed its 'at-the-market' (ATM) equity public offering, raising $3.11 million in gross proceeds through the sale of 595,560 shares at an average price of $5.23 per share. The company received net proceeds of $3.05 million, with no warrant coverage provided. As of September 18, 2024, SINTX had 1,342,853 shares outstanding, including the newly sold shares.
The funds will be used for general corporate purposes, including capital expenditures, working capital, potential acquisitions, and other business opportunities. This capital infusion aims to strengthen SINTX's position in ceramic manufacturing innovation, enabling rapid development, prototyping, and large-scale commercialization in aerospace & defense, medical devices, and industrial manufacturing sectors.
SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for a patent application covering novel methods of bonding bioactive silicon nitride to zirconia-toughened alumina (ZTA) surfaces. This innovation aims to enhance ZTA's biological properties, improving osseointegration and resistance to bacterial colonization.
The company, the only FDA-registered producer of implantable silicon nitride, has developed a particulate form that can be used in composites and coatings. This allows SINTX to upgrade existing devices and expand silicon nitride's applications to metallic and polymeric substrates.
SINTX's intellectual property portfolio now includes 16 issued U.S. patents and 84 pending worldwide patent applications, reinforcing its position in medical device biomaterial manufacturing.
SINTX Technologies (NASDAQ: SINT) has announced a series of strategic initiatives to strengthen its financial position and enhance long-term growth prospects. The company has raised additional capital through an At-The-Market (ATM) offering and implemented cost-reduction measures expected to result in over 50% reduction in cash used for operating expenses, lowering annual expenses by approximately $5.8 million.
SINTX is also in discussions with lessors to reduce lease obligations by the end of 2024. These measures are expected to extend the company's cash runway well into 2025. CEO Eric K. Olson emphasized the company's commitment to financial discipline while delivering value to stakeholders. SINTX is actively exploring strategic partnerships to enhance its competitive position and drive sustainable growth.
FAQ
What is the current stock price of SiNtx Technologies (SINT)?
What is the market cap of SiNtx Technologies (SINT)?
What does SINTX Technologies, Inc. specialize in?
What are the key features of SINTX's silicon nitride products?
Where have SINTX's spinal implants been successfully implanted?
Is SINTX Technologies FDA registered?
What other applications is SINTX involved in?
How does SINTX's silicon nitride benefit medical applications?
What are the recent achievements of SINTX Technologies?
Who can benefit from SINTX's products?
How does SINTX contribute to healthcare innovation?
Where can I find the latest news about SINTX Technologies?
